| A post by David Jensen in
| |
| | (iii) maintains the potential to
|
| californiastemcellreport on April 25 had
| |
| | differentiate into derivatives of
|
| some quotes relevant to CIRM's IP
| |
| | endoderm, mesoderm, and ectoderm tissues
|
| (intellectual property) Task Force
| |
| | throughout the culture, and
|
| meeting in March 2006 and to a meeting
| |
| | (iv) will not differentiate when
|
| schedulued for San Diego on Thursday,
| |
| | cultured on a fibroblast feeder
|
| April 27.--> Ed Penhoet, chair of the
| |
| | layer.First claim of US 6,200,806 (the
|
| task force, said last month's hearing
| |
| | application leading to the '806 patent
|
| raised some fundamental questions."What
| |
| | was a divisional of the application
|
| are we really attempting to do? Are we
| |
| | leading to the '780 patent) :A purified
|
| trying to drive therapies as rapidly as
| |
| | preparation of pluripotent human
|
| possible? Are we trying to stimulate
| |
| | embryonic stem cells which(i) will
|
| business in California? Do we want to
| |
| | proliferate in an in vitro culture for
|
| grow small companies? There (is) a whole
| |
| | over one year,
|
| set of potentially conflicting aims,"
| |
| | (ii) maintains a karyotype in which the
|
| Penhoet said.As a comment, one notes the
| |
| | chromosomes are euploid and not altered
|
| CIRM people need to get their act
| |
| | through prolonged culture,
|
| together to spend their money in a
| |
| | (iii) maintains the potential to
|
| coherent manner, and not have conflicting
| |
| | differentiate to derivatives of endoderm,
|
| aims. It's one thing if this is a WPA
| |
| | mesoderm, and ectoderm tissues throughout
|
| project for biologists; it's another
| |
| | the culture, and
|
| thing if one is trying to get royalties
| |
| | (iv) is inhibited from differentiation
|
| from patents, and it's still another
| |
| | when cultured on a fibroblast feeder
|
| thing to focus on getting a useful
| |
| | layer.Looking carefully, one will note
|
| product to market. The WPA project model
| |
| | that the basic preparation (first line)
|
| is the easiest to accomplish ("we spent a
| |
| | and all elements (i-iv) are different
|
| lot of money in an important area and
| |
| | between the basic claims of the two
|
| employed lots of scientists") but is most
| |
| | patents. For someone to get the type of
|
| likely to lead to disappointment.-->
| |
| | patent protection to encourage the
|
| Brad Margus, CEO of Perlegen Sciences of
| |
| | investment to bring a product to market,
|
| Mountain View, Ca., told the task force
| |
| | the person will need to get a broad
|
| that if CIRM wants to be an agent that
| |
| | claim, one that is not limited to the
|
| produces the next big thing in stem
| |
| | specific patient who will be the
|
| cells, it needs to minimize nonfinancial
| |
| | recipient of the "patient-specific" stem
|
| restrictions and heavy royalties."I'd
| |
| | cells. This need is apt to foster a
|
| like California to try to do it
| |
| | patent-thicket problem.Geron has
|
| differently ....and think a little
| |
| | exclusive rights in the Thomson patents
|
| smarter. If there really is a company out
| |
| | in certain areas. For investment, Geron
|
| there that has the next thing that you
| |
| | has sought private investors, largely
|
| need in stem cell research to happen, and
| |
| | ignoring the Congressional debates over
|
| your objective scientific advisors say
| |
| | expanding federal research dollars and
|
| this is what we want, you should be
| |
| | the vast bureaucracy that has held up
|
| really, really aggressive in getting it.
| |
| | state funding in California. "Given their
|
| And I'm concerned that some of these
| |
| | financial acumen, they are pretty much
|
| things that we're throwing out there,
| |
| | self-sustaining for the foreseeable
|
| like revenue sharing or the capping what
| |
| | future," says Steve Brozak, an analyst at
|
| a company (can earn), will only defeat
| |
| | WBB Securities, a brokerage based in San
|
| that purpose."As a comment, one "next big
| |
| | Diego. "They've managed that by tapping
|
| thing in embryonic stem cells" is to do
| |
| | into the capital markets. These folks
|
| what Hwang Woo-Suk claimed to have done
| |
| | have learned very well; they don't want
|
| in 2005: create patient specific
| |
| | to be caught at the mercy of anybody."
|
| embryonic stem cell lines. All the
| |
| | Geron has spent about $100 million in
|
| "objective science advisors" in the world
| |
| | stem cell research over the last 10
|
| failed to counsel anyone that Hwang's
| |
| | years, small in comparison to
|
| work was fraudulent, so one has to take
| |
| | California's potential of $3 billion over
|
| advice in this area with a grain of salt.
| |
| | the next 10 years. Geron announced it
|
| Beyond doing patient-specific stem
| |
| | expects to file for permission from the
|
| cells, one still needs to use such things
| |
| | Food and Drug Administration [FDA] to
|
| in some beneficial way to actually help
| |
| | begin trials for an
|
| human beings. That objective may be more
| |
| | embryonic-stem-cell-based therapy for
|
| than 10 years in the future. Most venture
| |
| | spinal-chord injuries this year.
|
| capitalists seem to think the time line
| |
| | [information and quote from
|
| for a real product is long.--> One
| |
| | smartmoney.com] Keep in mind, under 35
|
| executive from Genentech, which has only
| |
| | USC 271(e)(1) as interpreted in the Merck
|
| a peripheral stem cell interest, told the
| |
| | v. Integra case, anyone is pretty much
|
| task force that it takes something like
| |
| | free to infringe anyone else's patents
|
| $1 billion to push a product to market.
| |
| | for purposes of obtaining information
|
| He said that for every dollar in
| |
| | needed by the FDA.The Washburn article
|
| research, another $5 is need for
| |
| | was discussed in a previous ezine piece:
|
| development. And the odds of developing a
| |
| | Ebert, Lawrence. (2006, April 12). Los
|
| successful product once it starts
| |
| | Angeles Times Article Way Off Base on
|
| clinical testing on humans range from one
| |
| | Stem Cell Issues. EzineArticles.
|
| in three to one in five.As a comment, one
| |
| | Retrieved April 27, 2006, from
|
| has to be careful to note that an
| |
| | reluctance of venture capitalists to
|
| effective business model for
| |
| | invest in stem cell research is discussed
|
| patient-specific stem cells (geared to
| |
| | in an ezine piece: Ebert, Lawrence.
|
| INDIVIDUALS) is apt to be different from
| |
| | (2006, April 24). MIT Technology Review
|
| a business model for blockbuster drugs
| |
| | Concern Over WARF Patent Royalty Demand
|
| (geared to MANY PEOPLE taking the SAME
| |
| | To CIRM Over Stem Cells Is Misguided.
|
| drug).As some guidance, one can
| |
| | EzineArticles. Retrieved April 27, 2006,
|
| contemplate the basic composition of
| |
| | from B. Ebert is a registered patent
|
| matter claims of the Thomson/WARF
| |
| | attorney located in central New Jersey.
|
| patents, recently strongly criticized by
| |
| | He holds a Ph.D. from Stanford, a J.D.
|
| Washburn in the Los Angeles Times.First
| |
| | from the University of Chicago, maintains
|
| claim of US 5,843,780:A purified
| |
| | a blog at IPBiz.blogspot.com, and is the
|
| preparation of primate embryonic stem
| |
| | author of LESSONS TO BE LEARNED FROM THE
|
| cells which(i) is capable of
| |
| | HWANG MATTER: ANALYZING INNOVATION THE
|
| proliferation in an in vitro culture for
| |
| | RIGHT WAY, published in the Journal of
|
| over one year,
| |
| | the Patent & Trademark Office Society [88
|
| (ii) maintains a karyotype in which all
| |
| | JPTOS 239 (March 2006)]. Ebert is listed
|
| the chromosomes characteristic of the
| |
| | in Marquis Who's Who in America, Diamond
|
| primate species are present and not
| |
| | Edition, 2005. Ezine draft submitted
|
| noticeably altered through prolonged
| |
| | April 27, 2006.
|
| culture,
| |
| |
|
